Search Result

Results for "

ASCs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Adrenergic Receptor (1) AIM2 (2) Akt (4) Androgen Receptor (3) Apoptosis (2) ASCT (2) Caspase (4) CDK (2) Cytochrome P450 (2) Dopamine Transporter (1) Endogenous Metabolite (1) ERK (1) Fluorescent Dye (1) GPR55 (2) HIF/HIF Prolyl-Hydroxylase (1) HSP (1) IKK (1) Interleukin Related (5) Keap1-Nrf2 (1) MicroRNA (1) Mitophagy (1) NF-κB (3) NOD-like Receptor (NLR) (11) p38 MAPK (2) PD-1/PD-L1 (2) PI3K (3) Proteasome (1) Pyroptosis (3) Reactive Oxygen Species (ROS) (2) Reference Standards (1) Small Interfering RNA (siRNA) (2)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Inflammation/Immunology (13) Metabolic Disease (1) Neurological Disease (7)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

Inhibitors & Agonists

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149604

NLRP3-IN-21 1 Publications Verification	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-21 (compound L38) is a NLRP3 inflammasome inhibitor with inflammatory properties. NLRP3-IN-21 inhibits NLRP3 inflammasome activation and pyroptosis by suppressing gasdermin D cleavage, ASC oligomerization, and NLRP3 inflammasome assembly .

HY-144226

NLRP3/AIM2-IN-3 5+ Cited Publications	NOD-like Receptor (NLR) AIM2 Pyroptosis	Inflammation/Immunology
NLRP3/AIM2-IN-3 (compound 59) is a potent inhibitor with differential species specific effects against NLRP3 and AIM2 inflammasome-dependent pyroptosis. NLRP3/AIM2-IN-3 shows inhibitory efficacy against pyroptosis in THP-1 macrophages stimulated with LPS/nigericin, with an IC₅₀ of 0.077 ± 0.008 μM. NLRP3/AIM2-IN-3 disturbs the interaction of NLRP3 or AIM2 with the adaptor protein ASC and inhibited ASC oligomerization .

HY-W771599

ASC-69 APY69	PD-1/PD-L1	Cancer
ASC-69 (APY69)is a potent and promising?PD-1/PD-L1 small-molecule inhibitor .

HY-I1070

D-Isoleucine (R)-Isoleucine	ASCT	Neurological Disease
D-Isoleucine is a selective competitive activator of the Asc-1 antiporter (Ki=0.98 mM). D-Isoleucine promotes the release of D-serine and glycine by binding to the Asc-1 protein on the neuronal cell membrane, and enhances NMDA receptor-dependent synaptic plasticity. D-Isoleucine can be used in the study of neurodegenerative diseases (such as Alzheimer's disease and schizophrenia). D-Isoleucine also acts as a non-classical D-amino acid, interferes with bacterial peptidoglycan synthesis, and inhibits the formation of Staphylococcus aureus biofilm, and has potential antibacterial application value[1][2].

HY-120170

BMS-466442 1 Publications Verification	ASCT Adrenergic Receptor Dopamine Transporter	Neurological Disease
BMS-466442 is a potent and selective inhibitor of *asc-1* (alanine serine cysteine transporter-1), with an IC₅₀ of 11 nM. BMS-466442 inhibits [ ³H] D-serine uptake into rat brain synaptosomes, with an IC₅₀ of 400 nM. BMS-466442 can be used for schizophrenia research .

HY-15194

Dimethylcurcumin Maximum Cited Publications 14 Publications Verification ASC-J9; GO-Y025	Androgen Receptor	Cancer
Dimethylcurcumin (ASC-J9) is an androgen receptor degradation enhancer that effectively suppresses castration resistant prostate cancer cell proliferation and invasion.

HY-174312

NLRP3-IN-81	NOD-like Receptor (NLR) Pyroptosis Caspase Interleukin Related	Inflammation/Immunology
NLRP3-IN-81 (N102) is a BBB-penetrable inhibitor against NLRP3 inflammasome-dependent pyroptosis with an EC₅₀ of 0.029 μM against cell pyroptosis induced by Nigericin (HY-127019). NLRP3-IN-81 potently inhibits NLRP3-dependent activation of caspase-1 and the release of IL-1β. NLRP3-IN-81 disturbs the interaction of NLRP3 with the adaptor protein ASC and inhibits ASC oligomerization. NLRP3-IN-81 can be used for pyroptosis-related diseases research, such as inflammatory bowel diseases and type 2 diabetes .

HY-161329

NLRP3-IN-32	NOD-like Receptor (NLR) Reactive Oxygen Species (ROS) NF-κB IKK	Inflammation/Immunology
NLRP3-IN-32 (compound 7a), a 3, 4-dihydronaphthalene-1(2H)-one derivative, is a potential NLRP3 inflammatory vesicles inhibitor. NLRP3-IN-32 can block the assembly and activation of NLRP3 inflammasome by down-regulating the expression of NLPR3 and apoptosis-associated speck-like protein containing a CARD (ASC), and inhibiting the production of reactive oxygen species (ROS) and other inflammatory mediators. NLRP3-IN-32 inhibits the phosphorylation of IκBα and NF-κB/p65 and the nuclear translocation of p65, thereby inhibiting NF-κB signaling .

HY-163281

FSY-OSO2F	Fluorescent Dye	Cancer
FSY-OSO2F shows an uptake in MCF-7 cells through the regulation of L-Tyr, ASC, and ASC2 transporters. FSY-OSO2F can be used as a PET tracer, when labeled with ¹⁸F, and exhibits good uptake and good contrast in MCF-7 and 22Rv1 subcutaneous tumors .

HY-172134

NLRP3-IN-70	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-70 (Compound 5m) is an NLRP3 inflammasome inhibitor with low oral bioavailability. NLRP3-IN-70 can directly bind to the NACHT domain of the NLRP3 protein and block the interaction of NLRP3 and *ASC, thus inhibiting ASC* oligomerization and NLRP3 inflammasome assembly. NLRP3-IN-70 can be used in the research of sepsis and nonalcoholic steatohepatitis .

HY-RS21951

Sucla2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Sucla2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sucla2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sucla2 Mouse Pre-designed siRNA Set A Sucla2 Mouse Pre-designed siRNA Set A

HY-15194R

Dimethylcurcumin (Standard)	Androgen Receptor	Cancer
Dimethylcurcumin (Standard) is the analytical standard of Dimethylcurcumin. This product is intended for research and analytical applications. Dimethylcurcumin (ASC-J9) is an androgen receptor degradation enhancer that effectively suppresses castration resistant prostate cancer cell proliferation and invasion.

HY-156798

ADS032 1 Publications Verification	NOD-like Receptor (NLR) Interleukin Related	Inflammation/Immunology
ADS032 is a sulfonylurea compound that is an NLRP1 and NLRP3 inflammasome inhibitor. ADS032 reduces the secretion of inflammatory factors and inhibits the oligomerization of *ASC*. ADS032 has anti-inflammatory effects in a variety of inflammatory models and can be used in the study of inflammatory diseases .

HY-130480

Fructose-arginine	AIM2	Inflammation/Immunology
Fructose-arginine, an amino-sugar, is an AIM2 inflammasome activation inhibitor. Fructose-arginine attenuates the secretion of IL-1β, IL-18, and caspase-1, and Asc pyroptosome formation and Gsdmd cleavage resulting from AIM2 inflammasome activation .

HY-107541

O-1602 1 Publications Verification	GPR55	Neurological Disease
O-1602 is an agonist of GPR55 (G protein-coupled receptor 55). O-1602 reduces the number and activation of hippocampal microglia induced by METH (methamphetamine). O-1602 decreases the expression levels of NLRP3 inflammasome proteins, including NLRP3, ASC and Caspase-1 .

HY-RS14000

SUCLA2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SUCLA2 Human Pre-designed siRNA Set A contains three designed siRNAs for SUCLA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SUCLA2 Human Pre-designed siRNA Set A SUCLA2 Human Pre-designed siRNA Set A

HY-151252

NIC-0102	Proteasome NOD-like Receptor (NLR)	Inflammation/Immunology
NIC-0102 is an orally active proteasome inhibitor (pIC₅₀=7.55) that specifically inhibits NLRP3 inflammatory vesicle activation. NIC-0102 shows potent anti-inflammatory effects in a model of dextran sulfate sodium (DSS)-induced ulcerative colitis. NIC-0102 also inhibits production of pro-IL-1β .

HY-156374

D359-0396	NOD-like Receptor (NLR) Pyroptosis	Inflammation/Immunology
D359-0396 is an orally active NLRP3 inflammasome inhibitor. D359-0396 inhibits pyroptosis and IL-1β release in macrophages. D359-0396 also inhibits the oligomerization of NLRP3, ASC and the cleavage of GSDMD. D359-0396 alleviates EAE, and also improves survival after septic shock in mice .

HY-137442

Inupadenant 1 Publications Verification EOS-850	Adenosine Receptor	Cancer
Inupadenant is an orally active, highly selective A_2A receptor antagonist. Inupadenant can not cross BBB. Inupadenant can enhance the humoral immune response and has anti-tumor activity .

HY-107541R

O-1602 (Standard)	GPR55 Reference Standards	Neurological Disease
O-1602 (Standard) is the analytical standard of O-1602. This product is intended for research and analytical applications. O-1602 is an agonist of GPR55 (G protein-coupled receptor 55). O-1602 reduces the number and activation of hippocampal microglia induced by METH (methamphetamine). O-1602 decreases the expression levels of NLRP3 inflammasome proteins, including NLRP3, ASC and Caspase-1 .

HY-P99115

Envafolimab ASC 22; KN 035	PD-1/PD-L1	Cancer
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25 nM. Envafolimab has the potential for the research of solid tumors .

HY-161072

CSC-6	NOD-like Receptor (NLR)	Inflammation/Immunology
CSC-6 is a NLRP3 inhibitor. CSC-6 can significantly inhibit IL-1β secreted by PMATHP-1 cells with an IC₅₀ value of 2.3 μM. CSC-6 specifically binds NLRP3 and inhibits NLRP3 activation by blocking ASC oligomerization during NLRP3 assembly. CSC-6 effectively reduces the symptoms of NLRP3 overactivation-mediated sepsis and gout in mouse models .

HY-149127

Rosolutamide ASC-JM17; ALZ-003	Keap1-Nrf2 Androgen Receptor HSP Mitophagy	Metabolic Disease
Rosolutamide (ASC-JM17), a curcumin analog, is an orally active, potent Nrf1 and Nrf2 activator. Rosolutamide activates Nrf1, Nrf2 and heat shock factor 1 (Hsf1), thereby activating the expression of proteasome subunits, antioxidant enzymes and molecular chaperones. Rosolutamide degrades the polyglutamine (polyQ) androgen receptor (AR) via the ubiquitin-proteasome pathway and improves motor function in mouse models of spinal and bulbar muscular atrophy (SBMA). Rosolutamide improves mitochondrial function and promotes autophagy, decreases mutant protein aggregates, and attenuates intracellular/mitochondrial reactive oxygen species (ROS) levels .

HY-P4322

H-Ile-Lys-Val-Ala-Val-OH 1 Publications Verification	ERK Akt	Neurological Disease Cancer
H-Ile-Lys-Val-Ala-Val-OH is one of the most potent active sites of laminin-1. H-Ile-Lys-Val-Ala-Val-OH promotes cell adhesion, neurite outgrowth, and tumor growth. H-Ile-Lys-Val-Ala-Val-OH stimulates BMMSC population growth and proliferation by activating MAPK/ERK1/2 and PI3K/Akt signalling pathways .

HY-N1431

Tabersonine 2 Publications Verification	NOD-like Receptor (NLR) Apoptosis Cytochrome P450 NF-κB PI3K Akt CDK Caspase Interleukin Related p38 MAPK	Inflammation/Immunology Cancer
Tabersonine is a selective, orally active NLRP3 inhibitor. Tabersonine directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer .

HY-N1431A

Tabersonine hydrochloride	NOD-like Receptor (NLR) Apoptosis Cytochrome P450 NF-κB PI3K Akt CDK Caspase Interleukin Related p38 MAPK	Neurological Disease Inflammation/Immunology
Tabersonine hydrochloride is a selective, orally active NLRP3 inhibitor. Tabersonine hydrochloride directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine hydrochloride also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine hydrochloride can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine hydrochloride is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer .

HY-130413

Protectin D1 Neuroprotectin D1; NPD1	Endogenous Metabolite PI3K Akt HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Caspase Interleukin Related MicroRNA	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Protectin D1, a neuroprotectin D1 produced by neuronal cells, is a member of a newly discovered family of bioactive products derived from docosahexaenoic acid. Protectin D1 also serves as a specialized pro-resolving mediator, exhibiting effective in vivo pro-resolving activity in various human disease models. Additionally, Protectin D1 is an inhibitor of NALP3 inflammasomes and regulates the PI3K/AKT and HIF-1α signaling pathways. Protectin D1 exerts anti-inflammatory effects by reducing ROS levels, inhibiting the expression of NALP3, *ASC, and Caspase-1, and consequently decreasing the release of pro-inflammatory cytokines IL-1β* and IL-18. Furthermore, Protectin D1 enhances miRNA-210 expression, activates the PI3K/AKT signaling pathway, and exerts cardioprotective effects. Protectin D1 holds promise for research in cardiovascular diseases and inflammatory disorders .

Cat. No.	Product Name	Target	Research Area